Insider · CIK 0001643757

Bell Graeme

Reports to the SEC for 3 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001643757

Forms 4 and 5

Insider transactions

21 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2018-03-28	NTLAIntellia Therapeutics, Inc.M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+8,000 sh	$13.48	+$108K	21,400
2018-03-28	NTLAIntellia Therapeutics, Inc. · Stock Option (Right to buy)M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−8,000 sh	—	—	202,000
2018-01-25	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	EVP, Chief Financial Officer	AAward	+25K sh	—	—	25,000
2017-12-12	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	EVP, Chief Financial Officer	AAward	+72.5K sh	—	—	72,500
2017-11-03	NTLAIntellia Therapeutics, Inc.A Award	EVP, Chief Financial Officer	AAward	+5,000 sh	$22.04	+$110K	13,400
2017-06-02	NTLAIntellia Therapeutics, Inc.A Award	EVP, Chief Financial Officer	AAward	+8,400 sh	$12.37	+$104K	8,400
2017-01-03	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	EVP, Chief Financial Officer	AAward	+210K sh	—	—	210,000
2016-06-24	Anacor Pharmaceuticals, Inc.Performance Restricted Stock UnitsD Disposition to Issuer	Executive VP and CFO	DDisposition to Issuer	−5,000 sh	—	—	0
2016-06-24	Anacor Pharmaceuticals, Inc.D Disposition to Issuer	Executive VP and CFO	DDisposition to Issuer	−10.5K sh	$99.25	−$1.04M	0
2016-06-24	Anacor Pharmaceuticals, Inc.Performance Restricted Stock UnitsD Disposition to Issuer	Executive VP and CFO	DDisposition to Issuer	−8,008 sh	—	—	0
2016-06-24	Anacor Pharmaceuticals, Inc.Performance Restricted Stock UnitsD Disposition to Issuer	Executive VP and CFO	DDisposition to Issuer	−4,004 sh	—	—	0
2016-06-24	Anacor Pharmaceuticals, Inc.Stock Option (right to buy)D Disposition to Issuer	Executive VP and CFO	DDisposition to Issuer	−28.8K sh	—	—	0
2016-06-24	Anacor Pharmaceuticals, Inc.Stock Option (right to buy)D Disposition to Issuer	Executive VP and CFO	DDisposition to Issuer	−25.3K sh	—	—	0
2016-06-01	Anacor Pharmaceuticals, Inc.S Sale	Executive VP and CFO	SSale	−751 sh	$99.28	−$74.6K	10,255
2016-02-03	Anacor Pharmaceuticals, Inc.A Award	Executive VP and CFO	AAward	+5,000 sh	—	—	11,006
2016-02-03	Anacor Pharmaceuticals, Inc.Stock Option (right to buy)A Award	Executive VP and CFO	AAward	+25.3K sh	—	—	25,299
2016-02-03	Anacor Pharmaceuticals, Inc.Performance Restricted Stock UnitsA Award	Executive VP and CFO	AAward	+5,000 sh	—	—	5,000
2015-06-01	Anacor Pharmaceuticals, Inc.A Award	Executive VP and CFO	AAward	+6,006 sh	—	—	6,006
2015-06-01	Anacor Pharmaceuticals, Inc.Stock Option (right to buy)A Award	Executive VP and CFO	AAward	+28.8K sh	—	—	28,793
2015-06-01	Anacor Pharmaceuticals, Inc.Performance Restricted Stock UnitsA Award	Executive VP and CFO	AAward	+8,008 sh	—	—	8,008
2015-06-01	Anacor Pharmaceuticals, Inc.Performance Restricted Stock UnitsA Award	Executive VP and CFO	AAward	+4,004 sh	—	—	4,004

Recent filings

Accepted (ET)
Mar 304
Bell Graeme0001209191-18-022178
SEC(opens sec.gov)
Jan 294
Bell Graeme0001209191-18-005804
SEC(opens sec.gov)
Dec 144
Bell Graeme0001209191-17-065657
SEC(opens sec.gov)
Nov 34
Bell Graeme0001209191-17-059054
SEC(opens sec.gov)
Jun 54
Intellia Therapeutics, Inc.0001209191-17-037516
SEC(opens sec.gov)
Jan 54
Intellia Therapeutics, Inc.0001209191-17-002291
SEC(opens sec.gov)
Jun 244
Anacor Pharmaceuticals, Inc.0000950103-16-014334
SEC(opens sec.gov)
Jun 34
Anacor Pharmaceuticals, Inc.0001209191-16-125860
SEC(opens sec.gov)
Feb 54
Anacor Pharmaceuticals, Inc.0001209191-16-096102
SEC(opens sec.gov)
Jun 34
Anacor Pharmaceuticals, Inc.0000950103-15-004569
SEC(opens sec.gov)

Companies

Address

240 W 40TH STREET, OFFICE 205

NEW YORK, NY, 10018